Peptide News Digest

#Insulin-Aspart

2 stories

Regulatory · View digest

EMA Committee Backs Two Biosimilar Insulin Aspart Medicines and Warns Mounjaro May Make the Pill Less Reliable

At its November 9-12 meeting, the CHMP adopted positive opinions for Garzulys and Donrafylix, two biosimilar versions of the mealtime insulin aspart for adults and children aged 1 and older. The committee also adopted a letter to health professionals on Mounjaro (tirzepatide) and oral contraceptives: women using the pill are advised to add a barrier method for 4 weeks after starting Mounjaro and after each dose increase, or switch to a non-oral method.

Research · View digest

Biosimilar Insulin Aspart Rapilin Matched NovoRapid on Blood Sugar in 229 Chinese Patients With Type 1 Diabetes

In a retrospective study of records from 34 hospitals in China, published in Diabetes Therapy, HbA1c fell by an adjusted 1.90 percentage points on the biosimilar Rapilin (116 patients) and 1.59 points on Novo Nordisk's NovoRapid (113 patients). The difference was not statistically significant. Half of the patients were children or adolescents, and the authors reported similar dose stability and safety. Because the study was not randomized, it cannot rule out differences between the patients who received each insulin.